TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix
License supports lifecycle management of the PMN310 franchise, with options to extend TXP1 to ProMIS’s Parkinson’s and ALS programs
Cam...